Female Sexual Dysfunction - 09/05/19
, Elia Margarita Valladares Juarez, MDResumen |
Female sexual dysfunction can drastically diminish quality of life for many women. It is estimated that in the United States 40% of women have sexual complaints. These conditions are frequently underdiagnosed and undertreated. Terminology and classification systems of female sexual dysfunction can be confusing and complicated, which hampers the process of clinical diagnosis, making accurate diagnosis difficult. There are few treatment options available for female sexual dysfunctions, however, some interventions may be of benefit and are described. Additional treatments are in development. The development of clear clinical categories and diagnostic guidelines for female sexual dysfunction are of utmost importance and can be of great benefit for clinical and public health uses and disease-related research.
El texto completo de este artículo está disponible en PDF.Keywords : Female sexual dysfunction, Hypoactive sexual desire disorder, Sexual arousal disorder, Female sexual pain disorder
Esquema
| This article originally appeared in the Psychiatric Clinics of North America, Volume 40, Issue 2, June 2017. |
|
| E.M. Valladares Juarez has nothing to disclose. A.H. Clayton: Grants: Endoceutics, Inc.; Janssen; Sage Therapeutics; Takeda. Advisory Board Fee/Consultant Fee: Acadia; Alkermes; Allergan; AMAG Pharmaceuticals, Inc.; Fabre-Kramer; Lundbeck; Otsuka; Palatin Technologies; S1 Biopharma; Sage Therapeutics; Sprout Pharmaceuticals; Takeda. Royalties/Copyright: Ballantine Books/Random House; Changes in Sexual Functioning Questionnaire; Guilford Publications. Shares/Restricted Stock Units: Euthymics; S1 Biopharma. |
Vol 103 - N° 4
P. 681-698 - juillet 2019 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
